Compare STRIDES PHARMA SCIENCE with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs LUPIN - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE LUPIN STRIDES PHARMA SCIENCE/
LUPIN
 
P/E (TTM) x 7.6 107.6 7.1% View Chart
P/BV x 0.9 2.4 37.4% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 STRIDES PHARMA SCIENCE   LUPIN
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
LUPIN
Mar-19
STRIDES PHARMA SCIENCE/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,147986 116.3%   
Low Rs642720 89.1%   
Sales per share (Unadj.) Rs317.2369.5 85.9%  
Earnings per share (Unadj.) Rs7.813.4 58.5%  
Cash flow per share (Unadj.) Rs25.137.4 67.0%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs274.3303.7 90.3%  
Shares outstanding (eoy) m89.50452.49 19.8%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.82.3 122.1%   
Avg P/E ratio x114.063.6 179.1%  
P/CF ratio (eoy) x35.722.8 156.4%  
Price / Book Value ratio x3.32.8 116.1%  
Dividend payout %25.50-   
Avg Mkt Cap Rs m80,058386,064 20.7%   
No. of employees `0002.517.7 14.2%   
Total wages/salary Rs m4,34131,513 13.8%   
Avg. sales/employee Rs Th11,325.89,453.8 119.8%   
Avg. wages/employee Rs Th1,731.41,782.0 97.2%   
Avg. net profit/employee Rs Th280.1343.0 81.7%   
INCOME DATA
Net Sales Rs m28,394167,182 17.0%  
Other income Rs m9413,640 25.8%   
Total revenues Rs m29,334170,822 17.2%   
Gross profit Rs m3,96528,822 13.8%  
Depreciation Rs m1,54010,850 14.2%   
Interest Rs m1,9623,078 63.7%   
Profit before tax Rs m1,40318,534 7.6%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m-16838 -448.0%   
Extraordinary Inc (Exp) Rs m-436-3,400 12.8%   
Tax Rs m979,017 1.1%   
Profit after tax Rs m7026,066 11.6%  
Gross profit margin %14.017.2 81.0%  
Effective tax rate %6.948.7 14.3%   
Net profit margin %2.53.6 68.2%  
BALANCE SHEET DATA
Current assets Rs m24,836138,536 17.9%   
Current liabilities Rs m18,99361,299 31.0%   
Net working cap to sales %20.646.2 44.5%  
Current ratio x1.32.3 57.9%  
Inventory Days Days7184 84.7%  
Debtors Days Days113112 100.9%  
Net fixed assets Rs m34,289127,516 26.9%   
Share capital Rs m895905 98.9%   
"Free" reserves Rs m23,651136,517 17.3%   
Net worth Rs m24,546137,422 17.9%   
Long term debt Rs m15,51366,417 23.4%   
Total assets Rs m65,437279,494 23.4%  
Interest coverage x1.77.0 24.4%   
Debt to equity ratio x0.60.5 130.8%  
Sales to assets ratio x0.40.6 72.5%   
Return on assets %4.13.3 124.5%  
Return on equity %2.94.4 64.8%  
Return on capital %6.98.9 77.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69759,414 26.4%   
Fx outflow Rs m73522,282 3.3%   
Net fx Rs m14,96237,132 40.3%   
CASH FLOW
From Operations Rs m1,87116,660 11.2%  
From Investments Rs m5,826-32,825 -17.7%  
From Financial Activity Rs m-10,1577,441 -136.5%  
Net Cashflow Rs m-2,615-8,724 30.0%  

Share Holding

Indian Promoters % 27.7 46.6 59.4%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 37.8 11.3 334.5%  
FIIs % 8.6 31.9 27.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.1 256.4%  
Shareholders   56,241 98,259 57.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 70 Points Higher; Telecom and Banking Stocks Advance(Closing)

Indian share markets traded on a positive note throughout the day and ended marginally higher. The BSE Sensex rose over 350 points intraday.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Nov 15, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - SUN PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS